For research use only. Not for therapeutic Use.
Umeclidinium bromide (GSK573719A, CAT: I005226) is a muscarinic receptor antagonist primarily used in the treatment of chronic obstructive pulmonary disease (COPD). It belongs to a class of drugs known as long-acting anticholinergics. By blocking the action of acetylcholine at muscarinic receptors in the airways, umeclidinium helps to relax and widen the bronchial smooth muscles, leading to improved airflow and reduced symptoms in patients with COPD. It is typically administered through inhalation as a once-daily maintenance therapy to provide sustained bronchodilation and symptom relief. Umeclidinium bromide has shown efficacy in improving lung function and reducing exacerbations in patients with COPD.
| Catalog Number | I005226 |
| CAS Number | 869113-09-7 |
| Synonyms | diphenyl-[1-(2-phenylmethoxyethyl)-1-azoniabicyclo[2.2.2]octan-4-yl]methanol;bromide |
| Molecular Formula | C29H34BrNO2 |
| Purity | ≥95% |
| Target | Muscarinic Receptor |
| Solubility | 10 mM in DMSO |
| Storage | Store at -20°C |
| IUPAC Name | diphenyl-[1-(2-phenylmethoxyethyl)-1-azoniabicyclo[2.2.2]octan-4-yl]methanol;bromide |
| InChI | InChI=1S/C29H34NO2.BrH/c31-29(26-12-6-2-7-13-26,27-14-8-3-9-15-27)28-16-19-30(20-17-28,21-18-28)22-23-32-24-25-10-4-1-5-11-25;/h1-15,31H,16-24H2;1H/q+1;/p-1 |
| InChIKey | PEJHHXHHNGORMP-UHFFFAOYSA-M |
| SMILES | OC(C1=CC=CC=C1)(C2=CC=CC=C2)C34CC[N+](CC4)(CCOCC5=CC=CC=C5)CC3.[Br-] |
| Reference | 1: Ni H, Htet A, Moe S. Umeclidinium bromide versus placebo for people with chronic obstructive pulmonary disease (COPD). Cochrane Database Syst Rev. 2017 Jun 20;6:CD011897. doi: 10.1002/14651858.CD011897.pub2. Review. PubMed PMID: 28631387.<br /> |
